vs
Prestige Consumer Healthcare Inc.（PBH）とGIBRALTAR INDUSTRIES, INC.（ROCK）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $225.0M、GIBRALTAR INDUSTRIES, INC.の約1.3倍）。GIBRALTAR INDUSTRIES, INC.の前年同期比売上増加率が高い（24.9% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $26.2M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -12.3%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ジブラルタル・インダストリーズ社は、特殊建築資材、インフラ関連製品、再生可能エネルギー向け製品の製造・販売を行う有力企業です。換気システム、屋根用付属品、太陽光発電設置架台、造園用品などを取り扱い、主に北米の住宅・商業建設、クリーンエネルギー市場向けにサービスを提供しています。
PBH vs ROCK — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $225.0M |
| 純利益 | $46.7M | — |
| 粗利率 | 55.5% | 25.3% |
| 営業利益率 | 29.1% | 7.9% |
| 純利益率 | 16.5% | — |
| 売上前年比 | -2.4% | 24.9% |
| 純利益前年比 | -23.5% | — |
| EPS（希薄化後） | $0.97 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $225.0M | ||
| Q3 25 | $274.1M | $310.9M | ||
| Q2 25 | $249.5M | $309.5M | ||
| Q1 25 | $296.5M | $290.0M | ||
| Q4 24 | $290.3M | $180.1M | ||
| Q3 24 | $283.8M | $277.1M | ||
| Q2 24 | $267.1M | $273.6M | ||
| Q1 24 | $277.0M | $292.5M |
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | $-89.1M | ||
| Q2 25 | $47.5M | $26.0M | ||
| Q1 25 | $50.1M | $21.1M | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $54.4M | $34.0M | ||
| Q2 24 | $49.1M | $32.2M | ||
| Q1 24 | $49.5M | $24.9M |
| Q4 25 | 55.5% | 25.3% | ||
| Q3 25 | 55.3% | 26.6% | ||
| Q2 25 | 56.2% | 28.4% | ||
| Q1 25 | 57.3% | 26.8% | ||
| Q4 24 | 55.5% | 29.0% | ||
| Q3 24 | 55.5% | 29.4% | ||
| Q2 24 | 54.7% | 30.5% | ||
| Q1 24 | 54.8% | 28.9% |
| Q4 25 | 29.1% | 7.9% | ||
| Q3 25 | 29.1% | 12.8% | ||
| Q2 25 | 28.8% | 12.8% | ||
| Q1 25 | 29.8% | 8.8% | ||
| Q4 24 | 31.7% | 13.3% | ||
| Q3 24 | 29.7% | 15.6% | ||
| Q2 24 | 27.0% | 14.9% | ||
| Q1 24 | 29.7% | 10.8% |
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | -28.6% | ||
| Q2 25 | 19.0% | 8.4% | ||
| Q1 25 | 16.9% | 7.3% | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 19.2% | 12.3% | ||
| Q2 24 | 18.4% | 11.8% | ||
| Q1 24 | 17.9% | 8.5% |
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.86 | $-2.98 | ||
| Q2 25 | $0.95 | $0.87 | ||
| Q1 25 | $1.00 | — | ||
| Q4 24 | $1.22 | — | ||
| Q3 24 | $1.09 | $1.11 | ||
| Q2 24 | $0.98 | $1.05 | ||
| Q1 24 | $0.98 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $115.7M |
| 総負債低いほど良い | $1.0B | $0 |
| 株主資本純資産 | $1.8B | $950.4M |
| 総資産 | $3.5B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $115.7M | ||
| Q3 25 | $119.1M | $89.4M | ||
| Q2 25 | $139.5M | $43.3M | ||
| Q1 25 | $97.9M | $25.1M | ||
| Q4 24 | $50.9M | $269.5M | ||
| Q3 24 | $51.5M | $228.9M | ||
| Q2 24 | $34.3M | $179.1M | ||
| Q1 24 | $46.5M | $146.7M |
| Q4 25 | $1.0B | $0 | ||
| Q3 25 | $993.1M | $0 | ||
| Q2 25 | $992.7M | $0 | ||
| Q1 25 | $992.4M | $0 | ||
| Q4 24 | $992.0M | $0 | ||
| Q3 24 | $1.1B | $0 | ||
| Q2 24 | $1.1B | $0 | ||
| Q1 24 | $1.1B | $0 |
| Q4 25 | $1.8B | $950.4M | ||
| Q3 25 | $1.8B | $951.8M | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.8B | $1.0B | ||
| Q4 24 | $1.8B | $1.0B | ||
| Q3 24 | $1.7B | $1.0B | ||
| Q2 24 | $1.7B | $975.7M | ||
| Q1 24 | $1.7B | $940.2M |
| Q4 25 | $3.5B | $1.4B | ||
| Q3 25 | $3.4B | $1.4B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.4B | ||
| Q4 24 | $3.3B | $1.4B | ||
| Q3 24 | $3.3B | $1.4B | ||
| Q2 24 | $3.3B | $1.4B | ||
| Q1 24 | $3.3B | $1.3B |
| Q4 25 | 0.56× | 0.00× | ||
| Q3 25 | 0.54× | 0.00× | ||
| Q2 25 | 0.54× | 0.00× | ||
| Q1 25 | 0.54× | 0.00× | ||
| Q4 24 | 0.55× | 0.00× | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.00× | ||
| Q1 24 | 0.68× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $35.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $26.2M |
| FCFマージンFCF / 売上 | 26.6% | 11.7% |
| 設備投資強度設備投資 / 売上 | 1.1% | 4.1% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | — |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $120.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $35.5M | ||
| Q3 25 | $57.5M | $73.0M | ||
| Q2 25 | $79.0M | $44.9M | ||
| Q1 25 | $61.8M | $13.7M | ||
| Q4 24 | $65.1M | $19.9M | ||
| Q3 24 | $69.8M | $64.7M | ||
| Q2 24 | $54.8M | $36.5M | ||
| Q1 24 | $66.9M | $53.2M |
| Q4 25 | $75.3M | $26.2M | ||
| Q3 25 | $55.4M | $64.8M | ||
| Q2 25 | $78.2M | $27.3M | ||
| Q1 25 | $58.4M | $2.3M | ||
| Q4 24 | $63.5M | $14.1M | ||
| Q3 24 | $67.8M | $60.5M | ||
| Q2 24 | $53.6M | $33.5M | ||
| Q1 24 | $63.8M | $48.8M |
| Q4 25 | 26.6% | 11.7% | ||
| Q3 25 | 20.2% | 20.8% | ||
| Q2 25 | 31.3% | 8.8% | ||
| Q1 25 | 19.7% | 0.8% | ||
| Q4 24 | 21.9% | 7.8% | ||
| Q3 24 | 23.9% | 21.8% | ||
| Q2 24 | 20.1% | 12.2% | ||
| Q1 24 | 23.0% | 16.7% |
| Q4 25 | 1.1% | 4.1% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.3% | 5.7% | ||
| Q1 25 | 1.2% | 3.9% | ||
| Q4 24 | 0.5% | 3.3% | ||
| Q3 24 | 0.7% | 1.5% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 1.1% | 1.5% |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | 1.73× | ||
| Q1 25 | 1.23× | 0.65× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | 1.90× | ||
| Q2 24 | 1.12× | 1.13× | ||
| Q1 24 | 1.35× | 2.13× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
